RealPennies

Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox


What you feel with this company ? Are you willing to
11
2
2
Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $57.67 USD
Change Today -1.31 / -2.22%
Volume 14.2M
As of 2:54 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$58.52
Previous Close
$58.98
Day High
$58.88
Day Low
$57.32
52 Week High
10/30/14 - $59.03
52 Week Low
06/5/14 - $46.30
Market Cap
95.7B
Average Volume 10 Days
9.7M
EPS TTM
$1.70
Shares Outstanding
1.7B
EX-Date
10/1/14
P/E TM
34.0x
Dividend
$1.44
Dividend Yield
2.49%
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

Bristol-Myers Immune Drug Improves Lung Cancer Survival
Prudential Financial Takes Risk on $2.2 Billion L&G Portfolio
Bristol-Myers Tops Estimates on Strong Drug Sales
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit
Novartis Leukemia Treatment Yields High Remission Rate

bristol-myers squibb co (BMY) Related News

What's the Dollar Value of Online Patient Chatter?
It's Not Just Disruption: More Management Wisdom You Should Doubt
'Miracle' Data Could Lead to Cancer Cures
Buying Prescription Drugs Online Without Getting Burned

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Announces Results from Checkmate -063

Bristol-Myers Squibb Company announced results from CheckMate -063, a Phase 2 single-arm, open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, administered as a single agent in patients with advanced squamous cell non-small cell lung cancer (NSCLC) who have progressed after at least two prior systemic treatments with 65% receiving three or more prior therapies (n=117). With approximately 11 months of minimum follow up, the objective response rate (ORR, the study's primary endpoint) was 15% (95% CI = 8.7, 22.2) as assessed by an independent review committee (IRC) using RECIST 1.1 criteria and the median duration of response was not reached. The estimated one-year survival rate was 41% (95% CI = 31.6, 49.7) and median overall survival (mOS) was 8.2 months (95% CI = 6.05, 10.91). Historically, the expected one-year survival rate for third-line squamous cell NSCLC patients is approximately 5.5% - 18%. Grade 3-4 drug-related adverse events (AEs) were reported in 17.1% of patients. The most common Grade 3-4 AEs (greater than or equal to 2%) were fatigue (4.3%), pneumonitis (3.4%), and diarrhea (2.6%). Discontinuations due to drug-related AEs of any grade occurred in 12% of patients and there were two drug-related deaths in patients with multiple comorbidities and in the setting of progressive disease. Bristol-Myers Squibb's lung cancer research and development program is evaluating its approved and investigational immunotherapies - either as single agents or as part of combination regimens - across lines of therapy, histologies and biomarker expression. Among these are six ongoing Phase 3 trials. Four Phase 3 trials are evaluating Opdivo (nivolumab) as a single agent - three in previously treated patients (CheckMate -017, CheckMate -057 and CheckMate -153) and one in chemotherapy-naïve patients (CheckMate -026). Two Phase 3 trials evaluating Yervoy in combination with chemotherapy in newly diagnosed small cell lung cancer (Study -156) and squamous cell NSCLC (Study -104) are ongoing. Bristol-Myers Squibb has proposed the name Opdivo (pronounced op-dee-voh), which, if approved by health authorities, will serve as the trademark for nivolumab. About the Checkmate -063 Trial design & detailed results: Checkmate -063 is a Phase 2 single arm, open-label study designed to assess advanced squamous cell NSCLC patients who progressed after both platinum-based therapy and at least one additional systemic therapy with an ECOG Performance Status of 0 or 1 who were treated with Opdivo as a single agent 3mg/kg by intravenous infusion every two weeks until disease progression or treatment discontinuation (n=117). The primary endpoint was ORR as assessed by an IRC using RECIST 1.1 criteria. Responders were further characterized by duration of response. Secondary endpoints included investigator-assessed ORR. Overall survival, PFS and efficacy by PD-L1 expression status were exploratory endpoints. All treated patients had received at least two prior systemic regimens with 65% receiving greater than or equal to three prior therapies. 76% of patients were within three months of completion of their most recent therapy. The best response to the most recent prior systemic therapy was progressive disease in 61% of patients. With approximately 11 months of minimum follow up, the ORR was 15% (95% CI = 8.7, 22.2) as assessed by an IRC using RECIST 1.1 criteria and the median duration of response was not reached. The estimated one-year survival rate was 41% (95% CI = 31.6, 49.7) and mOS was 8.2 months (95% CI = 6.05, 10.91). An additional 26% of patients had stable disease with a median duration of six months (95% CI, 4.73, 10.91) giving a disease control rate (defined as partial response + stable disease) of 41%. For patients with quantifiable PD-L1 expression, responses were observed independent of PD-L1 status. Grade 3-4 drug-related AEs were reported in 17.1% of patients. The most common (greater than or equal to 2%) Grade 3-4 AEs were fatigue (4.3%), pneumonitis (3.4%), and diarrhea (2.6%). Drug-related AEs generally were manageable with corticosteroids and/or supportive care as per established safety algorithms. Discontinuations due to drug-related AEs of any grade occurred in 12% of patients and there were two drug-related deaths in patients with muliple comorbidities and in the setting of progressive disease.

OliPass Announces a Worldwide Discovery Alliance with Bristol-Myers Squibb for PNA-based Therapeutics

OliPass announced a worldwide strategic alliance with Bristol-Myers Squibb Company (BMS) to discover and develop therapeutics against multiple targets using OliPass' technology platform. Under the terms of the agreement, BMS will make an up-front payment and will provide certain research support payments to continue development of the technology. OliPass will be eligible to receive additional payments upon completion of certain objectives. In addition, OliPass will be eligible to receive development milestones and royalties on the sales of each product licensed to BMS under the Agreement as well as other milestones based on the level of licensed product sales.

Bristol-Myers Squibb Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

Bristol-Myers Squibb Company announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total revenues were $3,921 million compared with $4,065 million a year ago. Earnings before income taxes were $1,008 million compared with $818 million a year ago. Net earnings were $732 million compared with $692 million a year ago. Net earnings attributable to the company were $721 million or $0.43 per diluted share compared with $692 million or $0.42 per diluted share a year ago. Non-GAAP net earnings were $750 million or $0.45 per diluted share compared with $768 million or $0.46 per diluted share a year ago. For the nine months, the company's total revenues were $11,621 million compared with $11,944 million a year ago. Earnings before income taxes were $2,441 million compared with $2,022 million a year ago. Net earnings were $2,002 million compared with $1,845 million a year ago. Net earnings attributable to the company were $1,991 million or $1.19 per diluted share compared with $1,837 million or $1.11 per diluted share a year ago. Non-GAAP net earnings were $2,314 million or $1.39 per diluted share compared with $2,177 million or $1.31 per diluted share a year ago. The company is adjusting its 2014 GAAP EPS guidance range to $1.15 - $1.25 from $1.50 - $1.60 and confirming its non-GAAP EPS guidance range of $1.70 - $1.80. The company expects worldwide revenues between $15.2 billion and $15.8 billion, full-year gross margin as a percentage of revenues between 75% and 76%. The company expects an effective tax rate of 19% - 20%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $57.72 USD -1.26

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.35 USD +2.17
AstraZeneca PLC 4,544 GBp +43.50
Biogen Idec Inc $319.44 USD -1.56
Celgene Corp $106.88 USD -0.058
Novo Nordisk A/S kr268.70 DKK -2.70
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 33.3x
Price/Sales 5.6x
Price/Book 5.9x
Price/Cash Flow 33.1x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy
[at noodls] - "We are thrilled that a company with the oncology experience and expertise of Bristol-Myers Squibb will be advancing our first clinical asset with the potential to provide a significant improvement ...
  Read More...
7:03 am Bristol-Myers enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
  Read More...
Merck Shares Slip On Missed Revenue Despite 'Breakthrough' Designation For Cancer Treatment
  Read More...
Company News for October 27, 2014
  Read More...
Bristol Myers Squibb
  Read More...
Bristol-Myers Squibb
  Read More...
Bristol-Myers tops 3rd-qtr estimates as sales of top drugs sizzle
  Read More...
BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  Read More...
[$$] Bristol-Myers Sales, Profit Beat Estimates
  Read More...
Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results
[at noodls] - Posts Third Quarter GAAP EPS of $0.43 and Non-GAAP EPS of $0.45 Achieves Significant Regulatory Milestones for PD-1 Inhibitor Opdivo Launches Daklinza-Based Regimens for HCV Patients in Japan and Europe ...
  Read More...
Bristol-Myers beats 3rd-qtr forecasts as top drugs deliver
  Read More...
Bristol-Myers tops Street 3Q forecasts
  Read More...
Will Bristol-Myers
  Read More...
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit
  Read More...